Oncology

Here are stories covering recent research, treatment, strategy and moves from some of the nation's top cancer hospitals:

While still in contract negotiations, registered nurses at Dana-Farber Cancer Institute - Merrimack Valley in Methuen, Mass., voted 33 to 1 to authorize a one-day strike, the Massachusetts Nurses Association said in an NBC Boston report. 

Researchers at Los Angeles-based City of Hope recently announced promising results for a new chemotherapy pill that "appears to annihilate all solid tumors," according to research published Aug. 1 in Cell Chemical Biology. 

The FDA approved GSK's Jemperli (dostarlimab) in combination with carboplatin and paclitaxel for adults with primary advanced or recurrent endometrial cancer who are mismatch repair deficient or microsatellite instability-high.

The University of Texas MD Anderson Cancer Center in Houston earned the No. 1 spot on U.S. News & World Report's "2023-24 Best Hospitals for Cancer" rankings, released Aug. 1. 

Eleven major cancer centers, or health systems with notable ones, have made Forbes' 2023 list of best places to work in the U.S. for women. 

Injectable versions of some widely used cancer drugs may be excluded from the new Medicare price negotiations until the 2030s, Reuters reported July 28.

Cancer care pioneer Irwin Krakoff, MD, celebrated his 100th birthday July 20. 

Cancer treatment is more than its therapies, and hospitals are utilizing a number of medical practices, social determinants of health programs and technologies to make cancer care more accessible and effective.

Cancer's aggressive tendency to spread, grow and further deteriorate the bodies that house it, may be reversible making it become its own aggressor, attacking and destroying itself, according to research published July 26 in Nature.